CompanyHealthEnterprise
Star Therapeutics
Star Therapeutics is a South San Francisco clinical-stage biotech building first-in-class antibody medicines for serious diseases, with a 'pipeline-in-a-product' approach. Its lead asset VGA039, developed through subsidiary Vega Therapeutics, is a once-monthly subcutaneous monoclonal antibody targeting Protein S, now in Phase 3 for von Willebrand disease.
2018Founded
South San FranciscoHQ
$100M (cumulative through 2022)Series B / Stealth Emergence
biotechantibody therapyrare diseasevon willebrand diseasehematologyvga039